Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Myriad Genetics (MYGN) Change in Taxes (2016 - 2026)

Myriad Genetics has reported Change in Taxes over the past 16 years, most recently at -$1.8 million for Q4 2025.

Quarterly Change in Taxes fell 200.0% to -$1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.4 million through Dec 2025, down 780.0% year-over-year, with the annual reading at -$4.4 million for FY2025, 780.0% down from the prior year.
Change in Taxes was -$1.8 million for Q4 2025 at Myriad Genetics, down from -$500000.0 in the prior quarter.
Over five years, Change in Taxes peaked at $18.1 million in Q4 2021 and troughed at -$90.3 million in Q1 2021.
The 5-year median for Change in Taxes is -$500000.0 (2023), against an average of -$5.7 million.
The largest YoY upside for Change in Taxes was 102.02% in 2021 against a maximum downside of 13000.0% in 2021.
A 5-year view of Change in Taxes shows it stood at $18.1 million in 2021, then plummeted by 101.1% to -$200000.0 in 2022, then plummeted by 150.0% to -$500000.0 in 2023, then decreased by 20.0% to -$600000.0 in 2024, then tumbled by 200.0% to -$1.8 million in 2025.
Per Business Quant, the three most recent readings for MYGN's Change in Taxes are -$1.8 million (Q4 2025), -$500000.0 (Q3 2025), and -$2.1 million (Q1 2025).